UK peptide regulation: monthly overview

### UK peptide regulation items for 2026-08, by date and source

| Date | Source | Item | Summary |
| --- | --- | --- | --- |
| 2026-08-10 | MHRA announcement | UK first in Europe to authorise orforglipron for weight management and type 2 diabetes | As with all GLP-1 receptor agonists, the MHRA will keep the safety and effectiveness of orforglipron under close review. |
| 2026-08-10 | MHRA announcement | MHRA advises quarantine of medical devices supplied without appropriate conformity markings | The MHRA has become aware of a number of medical devices being supplied on the UK market that do not comply with the requirements of the UK Medical Device Regulations 2002 (UK MDR 2002) or with the EU Medical Devices… |
| 2026-08-07 | MHRA announcement | Taking medication this summer? What you need to know about sun and heat exposure | Some medicines can make you more sensitive to the sun or increase the risk of dehydration without you realising it. The MHRA is encouraging people to know the risks and stay protected this summer. |
| 2026-08-06 | MHRA announcement | MHRA approves remibrutinib for adults with chronic spontaneous urticaria | As with any medicinal product, the MHRA will keep the safety and effectiveness of remibrutinib under close review. |
| 2026-08-04 | MHRA announcement | The Innovative Licensing and Access Pathway grants Innovation Passports to investigational products for cancer and dementia | Innovative investigational products for liver cancer and dementia recognised through the Innovative Licensing and Access Pathway ahead of next application round opening. |
| 2026-07-30 | MHRA announcement | Pioneering AI health innovations regulatory sandbox launched | The London sandbox is a secure environment designed to safely test AI-enabled devices in a real-world environment so patients can benefit more quickly. |
| 2026-07-30 | MHRA announcement | Thousands of patients to benefit from new daily pill for serious heart condition following co-ordinated MHRA and NICE decisions | Aficamten is recommended by NICE at the same time it was approved by the MHRA, thanks to improvements driven by closer working between the two organisations. |
| 2026-07-29 | ASA | ASA Ruling on Bolt Healthcare Ltd t/a Bolt Pharmacy | The ASA upheld two issues against Bolt Healthcare's paid Facebook ads for Wegovy/Mounjaro, ruling the ads promoted prescription-only weight-loss medicines to the public via linked landing pages and failed to disclose commercial intent by presenting the content as independent review material. |
| 2026-07-29 | MHRA announcement | Beat the heat: MHRA urges people to take extra care with medical devices this summer | Simple steps to help keep your essential medical equipment working safely when temperatures rise. |
| 2026-07-29 | MHRA announcement | MHRA clarifies regulatory status of ambient voice technologies used in the NHS | The Medicines and Healthcare products Regulatory Agency has published guidance, developed in close partnership with NHS England, clarifying how existing medical device law applies to ambient voice technology (AVT) products… |
| 2026-07-24 | MHRA announcement | No summer shortcut for safe weight loss | As demand for weight-loss medicines continues to rise, the MHRA is reminding people how to use GLP-1 medicines safely, spot illegal sellers, and avoid diet changes that could interfere with their medicines. |
| 2026-07-21 | MHRA announcement | MHRA approves world's first lower-carbon beclometasone inhalers for patients with asthma | The new inhalers use a next-generation propellant designed to reduce environmental impact while maintaining the same established treatment. |
| 2026-07-21 | MHRA Drug Safety Update | Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension | The product information has been updated for all domperidone products, to include a contraindication for patients with confirmed or suspected phaeochromocytoma (a rare tumour of the adrenal gland), due to the risk of… |
| 2026-07-17 | MHRA announcement | Hot cars, hot luggage: why where you store your medicines matters this summer | As part of the ‘Summer-proof your health’ campaign, the MHRA is reminding people that heat and poor storage, at home or while travelling, can affect how well some medicines work. |
| 2026-07-16 | MHRA announcement | MHRA delivers record performance as 2025-26 Annual Report and Accounts confirms growing global influence | The Medicines and Healthcare products Regulatory Agency (MHRA) has published its 2025–26 Annual Report and Accounts highlighting a year of strong and consistent delivery as set out in the agency’s first Results and… |
| 2026-07-15 | ASA | ASA Ruling on Kind Patches Ltd | The ASA upheld two complaints against a Facebook ad for Kind Patches' 'GLP-1 Patch', finding it implied medicinal, prescription-GLP-1-equivalent effects without authorisation and that it was irresponsible for targeting breastfeeding mothers with weight-loss messaging. |
| 2026-07-15 | ASA | ASA Ruling on Phlo Technologies Ltd | The ASA upheld a complaint that a paid Facebook ad for a Morrisons Clinic weight-loss service run via Phlo Technologies breached the CAP Code because linked landing pages referenced named prescription-only weight-loss medicines (Wegovy, Mounjaro), amounting to promotion of a POM to the public. |
| 2026-07-15 | MHRA Drug Safety Update | Botulinum toxin type A products: updated warnings regarding risk of iatrogenic botulism | Cases of iatrogenic botulism have been reported following the therapeutic or cosmetic use of botulinum toxin containing products where the toxin’s effect extends beyond the area of treatment. Patients should seek immediate… |
| 2026-07-15 | MHRA announcement | UK-donor plasma given go-ahead for new medicines | Medicines and Healthcare products Regulatory Agency (MHRA) has approved the use of UK‑donor plasma for five high‑priority plasma-derived medicinal products. |
| 2026-07-15 | MHRA announcement | Updated warnings for botulinum toxin products following rare cases of botulism | The MHRA is strengthening safety warnings for all botulinum toxin type A products, following reports of rare cases of botulism linked to their use. |
| 2026-07-10 | MHRA announcement | Yellow Cards: bad in football; brilliant in patient safety | As football fans across the country get behind England, the MHRA wants to keep any Yellow Cards off the pitch – and instead let people know that Yellow Cards can make an important impact in a very different way by helping… |
| 2026-07-09 | MHRA announcement | Heat, travel and late nights: How summer can affect your medicines and how to stay safe | The MHRA is urging people to “summer-proof your health” as warmer weather, travel, and changing routines can affect how medicines and medical devices work, with simple steps to help prevent avoidable harm. |
| 2026-07-08 | MHRA announcement | Nerandomilast (Jascayd) approved to treat adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis | As with any medicinal product, the MHRA will keep the safety and effectiveness of nerandomilast under close review. |
| 2026-07-08 | MHRA announcement | Four sentenced to nearly 15 years combined jail time following major MHRA investigation into illegal online supply of medicines | The MHRA’s Criminal Enforcement Unit dismantled a multimillion-pound criminal network responsible for illegally supplying medicines. |

Source: gov.uk MHRA feeds plus a monthly web-search pass for ASA, Trading Standards and enforcement news